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Abstract
Background
The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting
1/100.000 live births. It is defined by upper limb anomalies and congenital
heart defects with variable severity. We describe a dramatic phenotype of a
male, 15-month-old patient being investigated for strict diagnostic criteria of
HOS.
Methods and results
Genetic analysis revealed a so far unpublished TBX5 mutation, which occurs de
novo in the patient with healthy parents. TBX5 belongs to the large family of
T-box transcription factors playing major roles in morphogenesis and cell-type
specification. The mutation located in the DNA-binding domain at position
920 (C?A) leads to an amino acid change at position 85 (proline ? thre-
onine). Three-dimensional analysis of the protein structure predicted a cis to
trans change in the respective peptide bond, thereby probably provoking major
conformational and functional alterations of the protein. The p.Pro85Thr muta-
tion showed a dramatically reduced activation (97%) of the NPPA promoter in
luciferase assays and failed to induce NPPA expression in HEK 293 cells com-
pared to wild-type TBX5 protein. The mutation did not interfere with the
nuclear localization of the protein.
Conclusion
These results suggest that the dramatic functional alteration of the p.Pro85Thr
mutation leads to the distinctive phenotype of the patient.
ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Introduction
The Holt–Oram syndrome (HOS) is an autosomal domi-
nant disorder affecting 1/100.000 live births. The syn-
drome was first described by Mary Holt and Samuel
Oram (Holt and Oram 1960). The syndrome is assigned
to the heart-hand syndromes and is characterized by
upper limb malformations and congenital heart disease
(CHD) (Holt and Oram 1960; Basson et al. 1994, 1997,
1999; Li et al. 1997). Diagnosis of HOS should be fol-
lowed by strict diagnostic criteria for HOS comprising the
presence of preaxial radial ray malformation of at least
one upper limb along with a personal or a family history
of septation defects and/or atrioventricular conduction
defects (McDermott et al. 2005). With these strict criteria
around 70% of the HOS patients show a mutation in the
TBX5 gene (OMIM #601620) (Lichiardopol et al. 2007).
Forty percent of HOS occur sporadically while the others
are inherited by one of the parents (Holt and Oram
1960). In the beginning, mutations within the TBX5 gene
not related to HOS have not been identified (Goldmuntz
2004). However, it became evident that TBX5 mutations
are also associated with nonsyndromic diseases such as
atrial fibrillation (Postma et al. 2008; Baban et al. 2014;
Guo et al. 2016; Ma et al. 2016) or dilated cardiomyopa-
thy (Zhang et al. 2015).
The correlation of the TBX5 genotype with the severity
of the clinical features of HOS remains a controversial
issue. The majority of TBX5 mutations cause both severe
cardiac and skeletal phenotypes. Missense mutations lead
to a large phenotype variation in the affected heart and
limb depending on the position within the DNA-binding
domain. It has been suggested that missense mutations at
the amino terminus of the DNA-binding domain cause
severe cardiac but milder skeletal abnormalities. On the
other hand, mutations at the C-terminus of the TBX5
gene are responsible for milder cardiac defects but severe
skeletal malformations (Basson et al. 1999). However, this
relation has been questioned when a larger number of
mutations and individuals were analyzed. Only two out
of 20 individuals showed a clinical HOS phenotype con-
sistent with the above mentioned prediction and even an
identical TBX5 mutation provoked a diverse clinical pic-
ture in first degree relatives (Brassington et al. 2003).
Thus, the parameters and factors determining the geno-
type–phenotype relationship in HOS still have to
be identified.
Upper limb defects are mostly bilateral, asymmetric and
concern the preaxial radial ray. This includes predomi-
nantly thumb abnormalities with enormous phenotype
variations (Poznanski et al. 1970; Basson et al. 1994; New-
bury-Ecob et al. 1996). Furthermore, the left side is more
significantly affected (Smith et al. 1979). Most observed
congenital heart defects are atrial septal defects (ASDs),
ventricular septal defects (VSDs) and defects of the cardiac
conduction system (Basson et al. 1997).
The main cause for HOS are mutations in the TBX5
gene located on chromosome 12q24. Members of the T-
box gene family contain a highly conserved DNA-bind-
ing motif of 180–190 amino acid residues (Simon 1999;
Murray 2001; Tada and Smith 2001). T-box genes are
essential for cell-type specification and morphogenesis
(Smith 1999). Mutations in many of the T-box genes
are associated with human developmental disorders
(Murray 2001). Examples are the CPX syndrome, caused
by mutations in the TBX22 gene (Braybrook et al.
2001), the DiGeorge syndrome (TBX1 mutations) (Lind-
say et al. 2001) and the ulnar-mammary syndrome
(TBX3 mutations) (Bamshad et al. 1997). More than 90
mutations within the TBX5 gene include nonsense, fra-
meshift or splice-site mutations, leading to dys-func-
tional proteins and resulting in haploinsufficiency are
described (Basson et al. 1997; Kimura et al. 2015). Of
these 90 mutations, more than 50 are missense muta-
tions and deposited in the NCBI database (http://
www.ncbi.nlm.nih.gov/SNP/). Furthermore, there are
also case reports describing intragenic duplications (Patel
et al. 2012) and translocations (Terrett et al. 1996)
within the TBX5 gene leading to HOS.
Here, we report a novel TBX5 mutation within a highly
conserved region of the TBOX domain which displays a
severely reduced biological activity.
Materials and Methods
Ethical compliance
All donors have signed an informed consent and the pro-
cedure was approved by the local ethical committee of
the medical faculty of the Technical University of Munich
(Project number 5737/13).
Patient and probands
The 15-month-old male patient was hospitalized with
typical signs of the Holt–Oram syndrome in February
2014. He was the second child of healthy parents. His
female sibling is three years older with a diagnosis of
atrial septal defect II (ASD II). During the normal
pregnancy there was no exposure to drugs, alcohol,
smoking or infections. Birth occurred spontaneously
with a weight of 3670 g and a length of 52 cm.
Echocardiography and radiographs were carried out for
the patient.
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Purification of genomic DNA from patient
and first degree relatives
Peripheral venous blood samples were taken from the
patient and both parents. Genomic DNA was purified
using the QIAamp DNA Blood Mini kit according to
the manufacturer0s recommendation (QIAGEN, Hilden,
Germany).
Amplification of genomic TBX5 sequences
by PCR and Sequencing
All eight coding exons of the TBX5 gene
(NM_000192.3) were amplified directly from genomic
DNA by PCR, using the primers shown in the table
(Table S1). Amplification of the genomic DNA frag-
ments was carried out with the Fast Start High Fidelity
PCR-System (Roche Diagnostics, Mannheim, Germany)
using 1x PCR reaction buffer containing 1.8 mM MgCl2,
dNTPs (200 lM each), 0.4 lM of each primer, 5%
DMSO and 1U Fast Start High Fidelity Enzyme Blend
in a final volume of 20 lL. A 4 min activation of the
Taq polymerase at 95°C was followed by 40 cycles of
95°C for 30 sec, 60°C for 30 sec, 72°C for 120 sec and a
final extension for 10 min at 72°C on a Biorad
C1000TM Thermal Cycler. Amplification of exon 5 and 9
was done using nested PCR. Therefore, 1 lL of the first
PCR reaction of exons 5 and 9 were amplified using the
same conditions with the nested primers shown in the
table (Table S1). PCR products were purified with the
high pure PCR purification kit (Roche Diagnostics) and
subjected to DNA sequencing at Source BioScience Ima-
genes (Berlin, Germany). Amplification of exon 4 was
done in two independent PCRs and was sequenced in
both cases. The sequences were blasted against the refer-
ence sequence of human TBX5 (accession number
NM_000192.3). The newly detected genetic variation has
been submitted to the database of single-nucleotide
polymorphisms (db SNP) at NCBI (http://ncbi.nlm.nih.-
gov/SNP/).
TBX5 protein structure and prediction of
functional effects of the mutation
The coordinates of the TBX5–DNA complex were down-
loaded from the RCSB website (http://www.rcsb.org/pdb,
(Berman et al. 2000), PDB identifier 2X6V) and pictures
of the interaction between TBX5 and DNA have been
generated using Discovery Studio Visualizer 4.5 (Accelrys
Software Inc., San Diego, CA). The potential influence of
the p.Pro85Thr mutation on the function has been
assessed by PolyPhen-2 v2.2.2r398 (http://genetics.bwh.
harvard.edu/pph2/) and MutationTaster (http://www.mu-
tationtaster.org/). The stability of the mutant protein was
assessed using iStable (http://predictor.nchu.edu.tw/
istable/).
Expression plasmids and site-directed
mutagenesis
The p.Pro85Thr point mutation of the HOS patient was
introduced into the wild-type human TBX5 sequence
(fully sequenced, clone IRATp970D0542D, SourceBio-
science, Nottingham, UK) in a pAW48 expression vector
(backbone pcDNA3.1 with a flag sequence prior to the
TBX5 sequence, a kind gift by Dr. A. Moretti, Klinikum
Rechts der Isar, Munich, Germany) by PCR-based site-
directed mutagenesis, using the QuikChange Site-direc-
ted Mutagenesis Kit (Stratagene, La Jolla, CA). The
mutated primer 50 GGCTGGAAGG CGGATGTTTAC-
CAGTTACAA AGTGAAGGTG 30 (mutated base in
bold) was used at a final concentration of 4 ng/lL
according to the manufacturer’s instruction. After
sequence verification of both the wild-type and mutated
TBX5 sequences, the constructs were used in functional
assays. Activity of the construct containing wild-type or
the mutated TBX5 was tested in four independent luci-
ferase assays.
Nuclear localization of TBX5 protein
HEK 293 cells were grown to approximately 80% con-
fluence on coverslides and transfected with wild-type or
mutated TBX5 sequences (150 ng of plasmid) with
FuGENE (Invitrogen, Darmstadt, Germany). Two days
after transfection cells were subjected to immunocyto-
chemistry. Cells were fixed with 4% paraformaldehyde
for 15 min at room temperature and permeabilized with
0.1% Triton-X-100 in PBS for 10 min. Unspecific bind-
ing was blocked with 5% normal goat serum (abcam,
ab7841, Cambridge, UK) for 30 min. Monoclonal mouse
anti-flag M2 (SIGMA, F1804, Munich, Germany) was
diluted 1:1000 and rabbit polyclonal anti-GAPDH IgG
(abcam, ab36840) was diluted 1:200. HEK 293 cells were
incubated with primary antibodies for 1 h. Secondary
antibodies goat anti-mouse IgG (H&L) Alexa-Fluor 488
(abcam, ab150113) and goat anti-rabbit IgG (H&L)
Alexa Fluor 555 (abcam, ab150078) were used at a 1:500
dilution for 1 h. All incubations were performed at
room temperature. After the last wash slides were air-
dried, mounted in Abcam mounting medium with DAPI
(abcam, ab104139), sealed with cover slips and evaluated
under a fluorescent microscope (Axiovert 200M, Zeiss,
Oberkochen, Germany).
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Luciferase reporter assay
HEK 293 cells were cultured in DMEM/Ham0s F12 (Bio-
chrome, Berlin, Germany) supplemented with 5% FCS
(HyClone, Cramlington, UK) in a humidified atmosphere
with 5% CO2. The reporter plasmid contains the NPPA
promoter which drives the expression of luciferase (pALI-
Lva/ANF-luciferase, a kind gift from Dr. Q. Wang, Cleve-
land, OH). HEK 293 cells were transfected with the
pAW48 expression vectors together with the reporter
plasmid using FuGENE HD (Invitrogen) according to the
manufacturer0s recommendation. Each well received
150 ng of both effector and reporter plasmid and 250 ng
of the pBluescript KSII plasmid which is not expressed in
mammalian cells to normalize the DNA amount. Trans-
fection efficiency in each well was normalized to a b-
galactosidase-expressing construct (pCMV b-Gal, added
at 50 ng/well) in an ELISA. After two days of incubation
cells were lysed in reporter lysis buffer (Promega, Madi-
son, WI), incubated for 10 min at room temperature and
frozen for at least 30 min at 80°C. Lysates were thawn,
shaked for 30 min at room temperature and centrifuged
for 2 min at 20.000 9 g. Ten lL of the supernatant were
mixed with 100 lL of substrate buffer and luciferase
activity was measured in a luminometer (Tecan, Crail-
sheim, Germany). The measured activity of each sample
was normalized to the b-galactosidase expression of the
sample. All samples have been tested in four independent
experiments each performed in triplicates.
Evaluation of transcriptional activity of
wild-type and mutant TBX5
HEK 293 cells were transiently transfected with the pAW48
expression vector harboring either wild-type or mutated
TBX5 sequences. Two days later, cells were lysed with RNA
lysis buffer (Peqlab, Erlangen, Germany). Total RNA was
purified, using the peqGOLD total RNA kit (Peqlab) and
reverse-transcribed into cDNA with M-MLV reverse tran-
scriptase (Invitrogen). Expression of NPPA (NM_006172.3),
TBX5 (NM_000192.3), b-ACTIN (NM_001101.3), CX40
(NM_005266.6), IRX4 (NM_016358.2), HEY2 (NM_012259.2),
ID2 (NM_002166.4), and TNNI3 (NM_000363.4) was eval-
uated on a LightCycler 1.5 (Roche Diagnostics) using the
following conditions: activation of Taq polymerase for
15 min at 95°C followed by 40 cycles with 15 sec at 94°C,
20 sec at 60°C, and 20 sec at 60°C.
Statistics
The significance of differences in luciferase activity was
evaluated using the unpaired Student’s t-test. A value of
P < 0.05 was considered to be statistically significant.
Results
Identification of a novel de novo mutation
p.Pro85Thr in exon 4 of the TBX5 gene in a
patient with Holt–Oram syndrome
The 15-month-old male patient displayed pronounced
and typical features of the Holt–Oram syndrome (HOS).
The left upper arm was dramatically shortened (hy-
poplasia) and the thumb on this side was completely
missing (agenesis). The right fore limb showed an aplasia
of the radius and a deformed, shortened thumb (Fig. 1A).
In addition, the mobility of both hands was reduced due
to a radial flexion. X-rays of the fore limbs confirmed
these clinical findings and displayed the radial aplasia of
the right fore limb and the malformation of the thumbs
(Fig. 1B). Furthermore, the chest X-ray indicated a
severely enlarged heart, with a strongly enhanced cardio-
thoracic ratio of 0.75 (Fig. 1C). In addition, the patient
showed distinct cardiac malformations including multiple
VSDs, a patent foramen ovale (PFO) and a severe insuffi-
ciency of the tricuspid valve (grade III). Echocardiography
clearly visualized the two VSDs with diameters of 0.8 cm
each (Fig. 1D).
Due to the characteristic and extraordinary severe HOS
phenotype we decided to sequence all coding exons of the
TBX5 gene directly from genomic DNA. In exon 4 we
detected a single-nucleotide change c.920_C>A leading to
an amino acid change from proline to threonine at amino
acid position 85 (Fig. 2). We then sequenced exon 4 of
the TBX5 gene in both parents who did not have any his-
tory of CHD or upper limb malformations. As expected
exon 4 revealed a native wild-type sequence in both cases
(Fig. 2). Thus, the detected point mutation was not
inherited but rather appeared de novo in the patient.
Three-dimensional structure of TBX5-DNA
interaction and conservation of the mutated
residue
The de novo p.Pro85Thr mutation is located within the
highly conserved TBOX domain which interacts with
the DNA. This mutation has not yet been deposited in
the NCBI dbSNP (www.ncbi.nlm.nih.gov/SNP) and the
NHLBI Exome variant server (evs.gs.washington.edu/EVS)
databases.
We first analyzed the potential effect of this mutation
within the context of the TBX5-DNA complex structure
(Stirnimann et al. 2010) (Fig. 3A). In the wild-type pro-
tein Phe84-Pro85 adopts the rare cis-peptide conforma-
tion (torsion angle x = 0°) (Fig. 3B) occurring with a
frequency of <0.3% in known protein structures (Weiss
et al. 1998) with >90% of instances involving a proline
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residue (Xaa-Pro, where Xaa might be any amino acid)
(Weiss et al. 1998). A mutation into threonine at position
85 very likely adopts the usual trans-conformation (tor-
sion angle x = 180°) leading to a local or even overall
misfolding of the TBX5 protein compromising its proper
function. Consistent with this, the iStable software pack-
age predicted a decrease in protein stability as a conse-
quence of this specific mutation.
The p.Pro85Thr de novo mutation of the HOS patient
is located within the DNA-binding TBOX domain which
spans amino acids 53 to 243 and is distal to the TBX5 C-
terminus (Fig. 3B), an essential element for binding the
target DNA sequence (Stirnimann et al. 2010). Conse-
quently, the most likely effect caused by the mutation will
be impairment of proper DNA recognition and binding.
An alignment of the human TBX5 protein sequence with
the TBX5 sequences of other mammalian and non-mam-
malian species revealed that the Pro85 residue is
completely conserved during evolution (Fig. 3C). In addi-
tion, we compared the TBX5 protein sequence with the
other members of the human T-box gene family. Simi-
larly, position Pro85 is absolutely conserved in all mem-
bers (Fig. 3D). Finally, the mutation was estimated with a
very high probability to be damaging by PolyPhen-2
(score 1.000) and disease causing by MutationTaster
(score 0.999).
Effect of the p.Pro85Thr mutation on NPPA
promoter activation
We tested the functional activity of the p.Pro85Thr
mutant on the cardiac-specific natriuretic peptide precur-
sor type A (NPPA) promoter which drives the expression
of the luciferase reporter gene. This promoter is well
known to be activated by TBX5 (Hiroi et al. 2001).
Indeed, wild-type TBX5 was able to induce a strong,
Figure 1. Upper limb anomalies and cardiac
defects of the patient. (A) Photographs of the
body and upper limbs showing the
deformation of the upper arms and thumbs on
both hands. (B) X-rays of both upper limbs. (C)
X-ray of the body. (D) Echocardiogram
showing the two VSDs (marked by *).
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Figure 2. Identification of the p.Pro85Thr mutation in the TBX5 gene. Chromatograms of exon 4 showing the sequences of the unaffected
parents and the c.920_C>A mutation of the HOS patient. For the parents, the forward sequences are shown.
Figure 3. Location and conservation of the p.Pro85Thr mutation. (A) Schematic view of the interaction between TBX5 and DNA. The location of
p.Pro85 and the cis-peptide bond is indicated. (B) Vicinity of Phe84-Pro85 and the TBX5 C-terminus involved in DNA binding. (C) Alignment of
human TBX5 protein sequence with TBX5 proteins of multiple species. (D) Alignment of human TBX5 protein with other members of the T-box
gene family. Numbers refer to amino acid positions of the human TBX5 sequence.
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more than 100-fold elevated response compared to the
empty vector (Fig. 4A). The p.Pro85Thr mutant showed a
dramatic, more than 95% reduced response, almost com-
parable to the activity of the empty vector (Fig. 4A).
Effect of p.Pro85Thr on expression of TBX5
target genes
We next addressed the potential of the p.Pro85Thr
mutant to activate the NPPA promoter directly in HEK
293 cells which do not express endogenous TBX5
(Fig. 4B). Upon transfection both the wild-type and the
mutant TBX5 were equally expressed in these cells
(Fig. 4B, C). Indeed, wild-type TBX5 was able to induce
NPPA gene expression while the p.Pro85Thr mutant
failed to do so (Fig. 4B, C). Thus, the transcriptional
activity of the mutant appears to be dramatically reduced
compared to wild-type TBX5. We have also evaluated the
effect of the p.Pro85Thr mutant on the induction of fur-
ther down-stream targets like CX40, IRX4, HEY2, ID2
and TNNI3. However, no effect was seen possibly due to
the high endogenous expression of these genes in HEK
293 cells (Figure S1 and Table S2).
Subcellular localization of the p.Pro85Thr
mutant
To perform its function as a transcription factor, the
TBX5 protein must enter the nucleus which is abolished
by some TBX5 mutations, at least in part (Fan et al.
2003). Therefore, we also compared the subcellular distri-
bution of the p.Pro85Thr mutant with that of wild-type
TBX5 protein. To that end HEK 293 cells were transfected
with expression vectors harboring flag-tagged native or
mutant TBX5 sequences. To visualize the cytoplasmic
compartment we performed an immunohistochemical
staining with an anti-GAPDH antibody. The distribution
of wild-type TBX5 was clearly restricted to the nucleus
with no signs of cytoplasmic staining (Fig. 5A). Similarly,
the p.Pro85Thr mutant also showed an exclusively nuclear
localization (Fig. 5B), suggesting that the transport to the
nucleus is not affected by the mutation. Thus, nuclear
exclusion may not be a mechanism for the impaired bio-
logical activity of this specific mutation.
Discussion
In the present paper we have identified a yet undescribed
point mutation in the TBX5 gene leading to an amino
acid change at position 85 from proline to threonine. The
diagnosis of HOS was made according to the strict diag-
nostic criteria (McDermott et al. 2005). The patient
shows severe and asymmetric radial malformations in
combination with multiple VSDs (“swiss cheese” VSD)
and therefore complied with all strict diagnostic criteria
for HOS. In approximately 70% of HOS patients the dis-
ease is associated with a mutation in the TBX5 gene,
including missense and nonsense mutations (Fan et al.
Figure 4. Functional analysis of the p.Pro85Thr mutant. (A)
Activation of NPPA promoter-driven luciferase activity in HEK 293
cells. Results are presented as the mean  SE of four independent
experiments. *P < 0.05, ***P < 0.001. (B) Induction of NPPA gene
expression (NM_006172.3) in HEK 293 cells after transfection with
wild-type or mutant TBX5 sequences. 1: untransfected, 2: wild-type
TBX5, 3: p.Pro85Thr TBX5, 4: aq.bidest. (C) qRT-PCR analysis of TBX5
(NM_000192.3) and NPPA expression in HEK293 cells. Fold gene
expression was determined after normalization to an internal control
(b-ACTIN, NM_001101.3).
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2003; Heinritz et al. 2005; Postma et al. 2008; Zhang
et al. 2014; Al-Qattan and Abou Al-Shaar 2015; Guo et al.
2015) which are mostly located in the DNA-binding
TBOX domain (Mori and Bruneau 2004). The majority
of these mutations are inherited while de novo TBX5
mutations occur rather sporadically (Baban et al. 2014).
The identified TBX5 mutation was not inherited but
rather occurred de novo as both parents displayed a wild-
type sequence.
The functional activity of TBX5 resides within the
DNA-binding TBOX domain which spans residues 52 to
243. The identified mutation is located in the N-terminal
region. Interaction studies using electrophoretic mobility
shift assay experiments showed that the N-terminal exten-
sion and the TBOX of TBX5 are essential for interaction
with NKX2.5, whereas the C-terminal domain is not
(Hiroi et al. 2001). The identified mutation affects the
proline 85 residue which adopts a rarely occurring cis-
peptide conformation (torsion angle x = 0°), a main-
chain conformation which is nearly exclusively observed
for proline residues combined with any other amino acid
(Craveur et al. 2013). Specific isomerases generate and
stabilize this high energetic structure (Schiene-Fischer
2015). In the TBX5 protein of the HOS patient proline
85 was changed to a threonine residue which results in a
switch to the common trans-conformation of the peptide
bond. This conformation alters the three-dimensional
structure of the mutated TBX5 protein around position
85, locally or even overall, likely affecting both folding
and biological function. Therefore, also the interaction
with other transcription factors to direct or cooperatively
activate downstream targets may be influenced and thus
may terminate in the dramatic phenotype of the patient.
Most of the TBX5 mutations result in a loss-of-function
Figure 5. Nuclear localization of wild-type (A)
and mutant (B) TBX5 protein. Distribution of
wild-type and mutant TBX5 was analyzed by
immunohistochemical staining using an anti-
flag antibody. Merged images show a
combined staining of nuclei (blue), cytoplasm
(red) and TBX5 (green). White arrows indicate
cytoplasmic areas around the nuclei of TBX5
expressing cells. Scale bars represent 20 lM.
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(Boogerd et al. 2010; Zhang et al. 2014; Kimura et al.
2015) and only a few of them show a gain-of-function
(Postma et al. 2008; Baban et al. 2014). TBX5 is known
to interact with promoter regions of several genes, includ-
ing cardiac-specific genes like NPPA. Therefore, we
assessed the potential of the p.Pro85Thr mutation to acti-
vate the NPPA promoter which is a well-known direct
target of TBX5 (Hiroi et al. 2001). Wild-type TBX5 pro-
tein strongly enhanced the activity of the NPPA promoter
while the activation by the p.Pro85Thr was reduced by
more than 95% suggesting a severe loss-of-function of the
mutated TBX5 protein. This effect is similar though even
more pronounced to that seen with other TBX5 muta-
tions located in that region which were also tested for
NPPA promoter activation. These mutations include
among others p.Gly80Arg (Ghosh et al. 2001; Hiroi et al.
2001), p.Met74Ile, pLeu94Arg (Boogerd et al. 2010) and
p.Pro132Ser (Guo et al. 2016). In addition, the mutated
p.Pro85Thr protein failed to induce the expression of the
NPPA gene upon transfection of HEK 293 cells. There-
fore, the mutation of TBX5 at the amino acid position 85
appears to dramatically reduce the transcriptional activity.
A regulation of the expression of other down-stream tar-
gets like CX40, IRX4, HEY2, ID2, and TNNI3 was not evi-
dent. This is most likely due to the fact that HEK 293
themselves express these genes abundantly. In addition,
their regulation might require additional cofactors present
in cells of the cardiac lineage but probably absent in HEK
293 cells.
Finally, we also explored nuclear exclusion as an addi-
tional mechanism to prevent proper transcriptional activ-
ity. Such a mechanism has been reported for other
factors (Zhang et al. 2014) and some TBX5 mutations
also provoke a cytoplasmic localization of TBX5, at least
in part (Fan et al. 2003). However, we did not see any
difference of the subcellular localization between the
wild-type and the mutated protein. This is in good
agreement with the results of Zaragoza and colleagues
who have identified the nuclear localization signal of
TBX5 at amino acid positions 325 to 327 (Zaragoza
et al. 2004) well apart from position 85. They postulated
the C-terminal region following the TBOX domain har-
bors a transactivation domain, including a nuclear local-
ization signal, which is far away from the mutated
position in our patient.
In summary, we have identified a yet unknown muta-
tion in the TBX5 gene leading to an amino acid change
at position 85 from proline to threonine. The mutation is
located in a region which is highly conserved across spe-
cies borders and all members of the T-box family. The
mutated protein displayed a dramatically reduced biologi-
cal activity and failed to activate the promoter and
expression of the NPPA gene. These severe functional
defects may causatively lead to the pronounced clinical
HOS phenotype of the patient.
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